We are live on ! Find out more
ENTX icon

Entera Bio
ENTX

10 hedge funds and large institutions have $2.44M invested in Entera Bio in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

30% more capital invested

Capital invested by funds: $1.87M → $2.44M (+$567K)

5.15% more ownership

Funds ownership: 8.95% → 14.1% (+5.1%)

17% less funds holding

Funds holding: 12 → 10 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
10
Holders Change
-2
Holders Change %
-16.67%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
4
Calls
$25K
Puts
–
Net Calls
+$25K
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
+$953K
2
TSS
Two Sigma Securities
New York
+$47.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$23.2K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$136

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$10.5K
2
Millennium Management
Millennium Management
New York
-$871
3
UBS Group
UBS Group
Switzerland
-$445
4
SCA
Stonebridge Capital Advisors
Minnesota
-$145
5
Simplex Trading
Simplex Trading
Illinois
-$59

ENTX Hedge Fund Activity: Q4 2023 in Review

10 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q4 2023, worth a combined $2.44M — up 30% from $1.87M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ENTX and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Knoll Capital Management, adding an estimated $953K. The largest seller was Citadel Advisors, exiting entirely with an estimated $10.5K sold.

  • 10 institutional investors held Entera Bio (ENTX) as of Q4 2023, down from 12 in Q3 2023.
  • Funds reported $2.44M of Entera Bio stock for Q4 2023, up 30% quarter-over-quarter.
  • 2 funds opened new Entera Bio positions in Q4 2023 and 4 closed out, a net change of -2 holders.
  • The largest Entera Bio buyer in Q4 2023 was Knoll Capital Management, an estimated $953K added.
  • The largest Entera Bio seller in Q4 2023 was Citadel Advisors, an estimated $10.5K sold.

Based on aggregated 13F filings for Q4 2023.